Ascentage Pharma, based on research at University of Michigan, has filed to list in Hong Kong having raised about $235m in funding.

Ascentage Pharma, a China-based oncology drug developer based on research at University of Michigan, has filed for an initial public offering in Hong Kong having raised $150m last month.

Founded in 2009, Ascentage is developing small-molecule drug treatments for cancer, hepatitis B virus and age-related diseases, and is currently overseeing 20 clinical trials for a total of seven product candidates in China, the US and Australia.

The technology is based on research undertaken at University of Michigan led by…